Molecular Heterogeneity in Primary and Metastatic Prostate Tumor Tissue
Abstract
Purpose: The overarching goal of the grant was to characterize molecular heterogeneity in multifocal prostate cancer. Aim 1 focused on heterogeneity in PTEN loss in tumor tissue and prostate cancer prognosis. Aim 2 aimed to compare gene expression profiles between primary and lymph node metastases Scope: During the grant term, Dr. Batista received IRB approval, completed coursework to augment her expertise in prostate cancer epidemiology, coordinated meetings with collaborators, aided in specimen and data collection for the proposed work, lead the statistical analyses, and published the findings in peer-reviewed journals. Major Findings: PTEN loss was heterogeneous in prostate cancer foci, and was predictive of disease relapse. In related manuscripts that Dr. Batista co-authored and published, tumor expression of PSMA and genetic mutations in the SOD2 gene were associated with prostate cancer progression. Dr. Batista also published a review article on AMPK activation in cancer in Molecular Cancer Research. Significance: The clinical significance of the project was to better characterize putative prognostic markers for prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2015
- Accession Number
- ADA621180
Entities
People
- Julie Batista
Organizations
- Harvard Medical School